ライフサイエンスコーパス: interleukin-2

1 modified vaccinia Ankara expressing MUC1 and interleukin 2.

2 d with impaired glycolysis and signaling via interleukin 2.

3 f both the magnitude of the TCR stimulus and Interleukin 2.

4 le by exogenous PD-1 blockade or addition of interleukin 2.

5 liferation in vitro that could be rescued by interleukin-2.

6 ecrosis factor-alpha, and to a lesser extent interleukin-2.

7 regulate CD69 surface expression and secrete interleukin-2.

8 cells, by enhancing their responsiveness to interleukin-2.

9 Subcutaneous interleukin 2 (1.5 million IU/d) was administered during

10 ; and T-cell cytokines interferon gamma, and interleukin 2, 10, and 17.

11 eased, were interleukin-4 (18.0 [6.0-54.2]), interleukin-2 (11.8 [4.3-32.2]), angiopoietin-2 (6.4 [1.

12 Recently, N-(4-(18)F-fluorobenzoyl)-interleukin-2 ((18)F-FB-IL2) was introduced as a PET tra

13 which include interferon alpha and gamma and interleukin 2, 2R, 6, 7, 12, 15, 17, and 18, across diff

14 forming cells (SFCs) of interferon gamma and interleukin 2, 4, 5, and 6 were counted by means of enzy

15 between the 2 groups for interferon gamma or interleukin 2, 4, or 5 (all P > .05).

16 ce was reported had higher concentrations of interleukin 2, 6, and 10, interferon gamma, tumor necros

17 of cytokines, including interferon-gamma and interleukins 2, 6, and 10 (IL-2, IL-6, and IL-10).

18 us infusion of autologous TILs and high-dose interleukin-2 [720 000 IU/kg] every 8 h).

19 -type cells and bypassed the requirement for interleukin-2 administration to sustain in vivo activity

20 Interleukin 2 and IL-15 are two closely related cytokine

21 defects in allogeneic T-cell proliferation, interleukin 2 and interferon gamma (IFN-gamma) productio

22 Infection decreased interleukin 2 and interferon gamma production as well as

23 CCL2, CCL4, CCL13, CCL17, CXCL8, CXCL10; and interleukin 2 and interferon gamma than children who sur

24 nefit from immunotherapies such as high-dose interleukin 2 and ipilimumab, which, by contrast with BR

25 evelopment of CD4(+) T cells that coproduced interleukin 2 and tumor necrosis factor alpha and were a

26 coproteins form supramolecular clusters with interleukin-2 and -15 receptors in lipid rafts of T cell

27 oth CD4(+) and CD8(+) T cells as measured by interleukin-2 and interferon-gamma production, respectiv

28 od-stage specific CD4(+) T cells coproducing interleukin-2 and tumor necrosis factor alpha (P = .003)

29 sus controls) and lower levels of binding to interleukins 2 and 10 core promoter regions of the trans

30 interferon-gamma/tumor necrosis factor-alpha/interleukin-2), and proliferation-related markers (CD119

31 fter dMNP delivery of AFV, interferon gamma, interleukin 2, and interleukin 4 production by HBsAg-spe

32 d the expression of T-bet, interferon gamma, interleukin 2, and the antiapoptotic molecule Bcl-2, whe

33 cterized for expression of interferon-gamma, interleukin 2, and tumor necrosis factor alpha and surfa

34 f CD4(+) T cells for detection of IFN-gamma, interleukin 2, and tumor necrosis factor alpha was perfo

35 culating levels of type 1 (interferon gamma, interleukin 2, and tumor necrosis factor alpha) and type

36 nd CD4+ T-cell (expressing interferon-gamma, interleukin-2, and CD40 ligand) responses were evaluated

37 ing protein and the induction of CD25, CD69, interleukin-2, and gamma-interferon.

38 the immunotherapeutic cytokines interferon, interleukin-2, and interleukin-4.

39 Interferon-gamma, interleukin-2, and tumor necrosis factor alpha (TNF-alph

40 Sustained production of IFN-gamma, interleukin-2, and tumor necrosis factor alpha was elici

41 Anti-interleukin-2 (anti-IL2) antibody has been covalently im

42 Interleukin-2 appeared to be the earliest, most sensitiv

43 lls produced tumor necrosis factor alpha and interleukin 2 at the intrahepatic level significantly mo

44 ascular endothelial growth factor A (VEGFA), interleukin-2, bone morphogenetic protein-10, VEGFC, and

45 ents T-cell-receptor-dependent production of interleukin 2 by 34-fold.

46 Measurements of model cytokine interleukin-2 concentrations from <20 fM to >200 pM were

47 to and stabilizes the interface between the interleukin-2 cytokine and one of its receptor subunits,

48 enhanced CD25 and CD69 expression, increased interleukin-2 expression, and improved proliferation of

49 t the first use to our knowledge of low-dose interleukin 2 for treating severe AA by promoting the re

50 Using this screen, we identified interleukin-2 gamma receptor (IL2Rgamma) as a critical g

51 l killer (NK)-cell differentiation defect in interleukin-2 gamma-chain receptor (IL2RG)/JAK3 severe c

52 ific effector molecules (TNFalpha, IFNgamma, interleukin 2, granzyme B, perforin, macrophage inflamma

53 21 HDV-specific 20mer peptides and exogenous interleukin 2, HDV-specific CD4+ and CD8+ T-cell respons

54 was associated with decreased expression of interleukin-2 high-affinity receptors (CD25), STAT3 sign

55 (1,300 peptides) using gamma interferon and interleukin-2 (IFN-gamma/IL-2) FluoroSpot analysis.

56 responses were screened by gamma interferon/interleukin-2 (IFN-gamma/IL-2) FluoroSpot using autologo

57 of T-helper type 1 intracellular cytokines (interleukin 2, IFN-gamma, and tumor necrosis factor alph

58 ting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-alpha-2b) and granulocyt

59 equencies of interferon gamma (IFN-gamma(+))/interleukin 2 (IL-2(+))/tumor necrosis factor alpha (TNF

60 of regulatory T cells (Treg cells) requires interleukin 2 (IL-2) and agonist T cell antigen receptor

61 unique transcriptional program and produced interleukin 2 (IL-2) and IL-10.

62 ria monocytogenes epitope, elicited distinct interleukin 2 (IL-2) and phosphorylated kinase Erk respo

63 er levels of interferon gamma (IFN-gamma) or interleukin 2 (IL-2) ELISpot responses compared with eac

64 Interleukin 2 (IL-2) promotes Foxp3(+) regulatory T (Tre

65 onventional CD8(+) T cells down-regulate the interleukin 2 (IL-2) receptor alpha (IL2RA, or CD25) pro

66 e introduction of a targeted mutation in the interleukin 2 (IL-2) receptor common gamma chain (IL2rg(

67 epletion of IFN-gamma or genetic deletion of interleukin 2 (IL-2) receptor common gamma chain in Rag-

68 to agonist-driven TCR signals combined with interleukin 2 (IL-2) receptor signalling.

69 tumor necrosis factor alpha (TNF-alpha), and interleukin 2 (IL-2) secretion by CD8(+) T cells.

70 ptor (TCR) but does not affect PMA-activated interleukin 2 (IL-2) secretion.

71 TRAF3 dampened interleukin 2 (IL-2) signaling by facilitating recruitme

72 Interleukin 2 (IL-2) signaling through the IL-2 receptor

73 CD8(+) T cells by inflammatory mediators and interleukin 2 (IL-2) via pathways dependent on the metab

74 Interleukin 2 (IL-2) was an important upstream regulator

75 ncludes simian immunodeficiency virus (SIV), interleukin 2 (IL-2), and IL-15 DNAs, recombinant modifi

76 NF-alpha), gamma interferon (IFN-gamma), and interleukin 2 (IL-2), as well as IL-17, in both lungs an

77 flammatory cytokines in the serum, including interleukin 2 (IL-2), IL-6, IL-12 (p70), tumor necrosis

78 rted their regulatory function by inhibiting interleukin 2 (IL-2)-dependent de novo differentiation o

79 GM-CSF is strongly induced by interleukin 2 (IL-2).

80 enes or altered ability to sense and consume interleukin 2 (IL-2).

81 (TH1 cells) exposed to low concentrations of interleukin 2 (IL-2).

82 on of CD8alpha but not PD1, TIM-3, CTLA4, or interleukin 2 (IL-2).

83 d levels of interferon gamma (IFN-gamma) and interleukin 2 (IL-2; markers of VZV-specific cell-mediat

84 asymmetric partitioning of the receptor for interleukin 2 (IL-2Ralpha) during mitosis.

85 compared to CD8(+) T cells) that coexpressed interleukin-2 (IL-2) (66.4%) and/or tumor necrosis facto

86 tumor necrosis factor alpha (TNF-alpha), and interleukin-2 (IL-2) (P < 0.001) and splenic and lung CD

87 nfiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted pati

88 maintained CD25 expression and responded to interleukin-2 (IL-2) and CD27, which together programmed

89 ne function via changes to cytokines such as interleukin-2 (IL-2) and IL-10 and may predict disease p

90 Interleukin-2 (IL-2) and IL-15 play pivotal roles in T c

91 We compared the ability of interleukin-2 (IL-2) and IL-15 to sustain human NK-cell

92 to selectively up-regulate the production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) an

93 -associated CXCR3/CCR5 and TNFalpha/IFNgamma/interleukin-2 (IL-2) and less TH2-associated CCR3/CCR4,

94 The pleiotropic actions of interleukin-2 (IL-2) are essential for regulation of imm

95 ccination induced an increased expression of interleukin-2 (IL-2) by Gp120-specific CD4(+) T cells in

96 peutic regimen of low-dose recombinant human interleukin-2 (IL-2) combined with low-dose rapamycin to

97 Injection of Interleukin-2 (IL-2) complexed with a particular anti-IL

98 on ligand interaction; and, second, relative interleukin-2 (IL-2) deprivation.

99 e data obtained with overlapping peptides in interleukin-2 (IL-2) enzyme-linked immunosorbent spot (E

100 ay, normally activated by cytokines from the interleukin-2 (IL-2) family to promote cell proliferatio

101 consisting of the immunostimulatory cytokine interleukin-2 (IL-2) genetically fused to an antibody sp

102 Interleukin-2 (IL-2) has an essential role in the expans

103 Interleukin-2 (IL-2) has both pro- and anti-inflammatory

104 ifferentiation and in particular the role of interleukin-2 (IL-2) in promoting or inhibiting Th diffe

105 glucose metabolism is sufficient to support interleukin-2 (IL-2) induction.

106 Low-dose interleukin-2 (IL-2) inhibited unwanted immune responses

107 Interleukin-2 (IL-2) is a component of most protocols of

108 Interleukin-2 (IL-2) is a critical cytokine for the home

109 Interleukin-2 (IL-2) is a cytokine that has multiple inf

110 Interleukin-2 (IL-2) is a fundamental cytokine that cont

111 Interleukin-2 (IL-2) is a pleiotropic cytokine produced

112 Interleukin-2 (IL-2) is a pleiotropic cytokine that regu

113 Interleukin-2 (IL-2) is a potent cytokine with roles in

114 Interleukin-2 (IL-2) is a small alpha-helical cytokine t

115 High dose interleukin-2 (IL-2) is active against metastatic melano

116 tigen on ACT cells (Thy1.1) or an engineered interleukin-2 (IL-2) molecule on an Fc framework as targ

117 filtrating CD4(+), and this was prevented by interleukin-2 (IL-2) neutralization.

118 ly, antibody-mediated blockade of IFN-gamma, interleukin-2 (IL-2) or interleukin-15 receptor beta (IL

119 S) can rapidly and dose-dependently suppress interleukin-2 (IL-2) production and T cell proliferation

120 lpha (TNF-alpha), gamma IFN (IFN-gamma), and interleukin-2 (IL-2) production.

121 B7 ligand-mediated T cell proliferation and interleukin-2 (IL-2) production.

122 Treg cells led to reduced expression of the interleukin-2 (IL-2) receptor alpha subunit CD25, accumu

123 ody, Toll-like receptor 7 (TLR7) agonist and interleukin-2 (IL-2) reduced T cell apoptosis but did no

124 Interleukin-2 (IL-2) regulates lymphocyte function by si

125 Low-dose interleukin-2 (IL-2) represents a new therapeutic approa

126 ed with markedly reduced CD25 expression and interleukin-2 (IL-2) responsiveness, diminished CTLA-4 e

127 multiple sclerosis (RRMS) because of altered interleukin-2 (IL-2) secretion and IL-2 receptor (IL-2R)

128 T cells inhibited T cell receptor (TCR) and interleukin-2 (IL-2) signaling and upregulated PD-1, lea

129 tion of kynurenine correlates with defective interleukin-2 (IL-2) signaling in memory CD4 T cells fro

130 Given the importance of interleukin-2 (IL-2) signaling in the generation and fun

131 iation of pathogenic Trm cells revealed that interleukin-2 (IL-2) signaling was required for residenc

132 is dependent upon T cell receptor (TCR) and interleukin-2 (IL-2) signaling.

133 ), donor T(regs) failed to engraft even with interleukin-2 (IL-2) support.

134 tumor necrosis factor alpha (TNF-alpha), and interleukin-2 (IL-2) than control cows, whereas only cli

135 design mimics of the central immune cytokine interleukin-2 (IL-2) that bind to the IL-2 receptor beta

136 ase 1 studies identified a low daily dose of interleukin-2 (IL-2) that was well tolerated, did not ex

137 cal models and patients undergoing high-dose interleukin-2 (IL-2) therapy.

138 d the sensitivity of T cells to the cytokine interleukin-2 (IL-2) through a positive feed-forward loo

139 ering therapeutic doses of recombinant human interleukin-2 (IL-2) to AGMs, we show here that this mec

140 tumor necrosis factor alpha (TNF-alpha), and interleukin-2 (IL-2) were detected in splenocytes.

141 frequency of interferon-gamma (IFN-gamma)(+) interleukin-2 (IL-2)(-) CD8(+) T cells (r = -0.6, P = 0.

142 -fold (CI, 3.5- to 18.0-fold; P < 0.001) for interleukin-2 (IL-2), and 1.7-fold (CI, 0.1- to 4.0-fold

143 py with cisplatin, vinblastine, dacarbazine, interleukin-2 (IL-2), and interferon alfa as part of a c

144 with reduced expression of interferon-gamma, interleukin-2 (IL-2), and soluble IL-2Ralpha, but did no

145 d through the in vitro addition of exogenous interleukin-2 (IL-2), and the in vivo blockade of the re

146 PD-1 blockade strongly augmented IFN-gamma, interleukin-2 (IL-2), and TNF-alpha production.

147 re elevated frequencies of T cells producing interleukin-2 (IL-2), IL-10, and IL-17 and decreased IL-

148 seen for C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1alpha, transforming growth fac

149 r frequencies of CD4(+) T cells that express interleukin-2 (IL-2), IL-4, and tumor necrosis factor al

150 amma(c), is a component of the receptors for interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15, and IL-21

151 Treatment with cytokine interleukin-2 (IL-2), IL-4, IL-7, or IL-15 renders CD4(+

152 e show that the T cell homeostatic cytokines interleukin-2 (IL-2), IL-7, and IL-15 can induce CD4 dow

153 4+ T cells was induced in vitro by anti-CD3, interleukin-2 (IL-2), IL-7, or IL-15 but not by Toll-lik

154 at distinguished LTBI from controls included interleukin-2 (IL-2), monocyte chemotactic protein 2 (MC

155 ma, tumor necrosis factor alpha (TNF-alpha), interleukin-2 (IL-2), perforin, and CD107a.

156 Interferon-alpha (IFN-alpha), interleukin-2 (IL-2), tumor necrosis factor-alpha (TNFal

157 PB CD4(+) T cells produced predominantly interleukin-2 (IL-2), whereas CD4(+) and CD8(+) T-cell s

158 in subjects carrying HLA-B -21M or 21T using interleukin-2 (IL-2)-activated NK cells and leukemic cel

159 h factor-beta (TGF-beta)-activated Smad3 and interleukin-2 (IL-2)-activated Stat5 facilitated Tet1 an

160 These data identify the interleukin-2 (IL-2)-mTORc1 axis as a critical orchestra

161 e investigated the regulation of the size of interleukin-2 (IL-2)-producing CD4(+) T cell (IL-2p) poo

162 We found that aspects of the interleukin-2 (IL-2)-sensitive effector gene program in

163 (TCR) and pro-inflammatory cytokines such as interleukin-2 (IL-2).

164 ining magnetite and the T-cell growth factor interleukin-2 (IL-2).

165 associated with diminished DC expression of interleukin-2 (IL-2).

166 with DNA simian immunodeficiency virus (SIV)/interleukin-2 (IL-2)/IL-15, SIV Gag/Pol/Env recombinant

167 y, while T cell receptor (TCR) signaling and interleukin-2 (IL-2)/STAT5 activation support the suppre

168 n FOXP3(hi), CD127(lo) Tregs), expresses the interleukin-2 (IL-2)/STAT5 pathway and cell-cycle commit

169 tumor necrosis factor alpha [TNF-alpha], and interleukin 2 [IL-2]) and cytolytic molecules (granzyme

170 or [gammadelta-TCR]) and cytokines examined (interleukin 2 [IL-2], IL-4, IL-10, IL-17A, and gamma int

171 revealed a defect in the expression of CD25 (interleukin-2 [IL-2] receptor alpha chain) on Ad5-elicit

172 tumor necrosis factor alpha [TNF-alpha], and interleukin-2 [IL-2]) and type 17 (IL-17A and/or IL-17F)

173 ma and/or tumor necrosis factor [TNF] and/or interleukin-2 [IL-2])-producing CD4(+) and CD8(+) T cell

174 secretion of candidate cytokines/chemokines (interleukin-2 [IL-2], IL-6, IL-10, MIP-1alpha, and RANTE

175 yze T-cell activation markers (CD107, CD154, interleukin-2 [IL-2], tumor necrosis factor [TNF], and I

176 PREX1-Rac1-signaling pathway that stabilizes interleukin-2(IL-2), IL-4, and IL-10 messenger RNA (mRNA

177 The pleiotropic cytokine interleukin 2 (IL2) disrupts the blood-brain barrier and

178 zed Nfkappab1 mRNAs and reduced secretion of interleukin-2 (IL2) and interferon-gamma (IFNgamma), two

179 nes, including IFNgamma, interleukin 12, and interleukin 2 in plasma of Pip4k2c(-/-) mice.

180 SCM cells had increased abilities to secrete interleukin-2 in response to viral antigen, while secret

181 o support the role of CD28 costimulation and interleukin-2 in Treg homeostasis.

182 In T cells, the Tec family kinase, interleukin-2-induced tyrosine kinase (ITK), phosphoryla

183 hibitor of both Bruton's tyrosine kinase and interleukin-2 inducible kinase (ITK), has been used to t

184 The absence of the Tec family kinase Interleukin-2 inducible T cell kinase (Itk) results in T

185 Itk (interleukin-2 inducible T cell kinase) is a non-receptor

186 Interleukin-2 inducible T-cell kinase (ITK), a member of

187 Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing the

188 Nef interacts with interleukin-2-inducible T-cell kinase (Itk) and Bruton's

189 Interleukin-2-inducible T-cell kinase (ITK) and resting

190 Here we demonstrate that interleukin-2-inducible T-cell kinase (Itk) signaling in

191 hibits Bruton tyrosine kinase in B cells and interleukin-2-inducible T-cell kinase in T cells.

192 alogue obtained was effective at suppressing interleukin-2 induction in mice.

193 On the other hand, sex, CMV mismatch, interleukin-2 inhibitors, corticosteroids for rejection,

194 Expression of proinflammatory cytokines interleukin 2, interferon gamma, tumor necrosis factor a

195 week 24 with appearance of HIV gag-specific interleukin 2, interferon-gamma, and CD107a responses in

196 have been conjugated via this method include interleukin-2, interferon-alpha, ubiquitin, antibodies a

197 f proinflammatory and profibrotic cytokines (interleukin-2, interferon-gamma, and interleukin-17) whe

198 tiation of ART using intracellular cytokine (interleukin-2, interferon-gamma, tumor necrosis factor-a

199 Serological, antigen-specific B-cell, and interleukin 2-, interferon gamma-, and tumor necrosis fa

200 m antigen, and interferon gamma (IFN-gamma), interleukin 2, interleukin 10, and tumor necrosis factor

201 heir HLA-matched siblings in the presence of interleukin 2, interleukin 15, and rapamycin.

202 vels of interferon gamma, interleukin 1beta, interleukin 2, interleukin 6, and interleukin 13 were si

203 terferon gamma (IFNgamma), interleukin1beta, interleukin 2, interleukin 6, interleukin 10 (IL-10), an

204 They secrete interferon-gamma, interleukin-2, interleukin-10, and tumor necrosis factor

205 gnificantly higher admission serum levels of interleukin-2, interleukin-12, interferon-gamma, and tum

206 Level of interleukin-1beta, interleukin-2, interleukin-4, interleukin-5, interleukin

207 at this infection leads to the production of interleukin-2, interleukin-6, and transforming growth fa

208 ammatory cytokines (e.g., interleukin-1beta, interleukin-2, interleukin-6, interleukin-8, and monocyt

209 lysis further implicates IFNgamma, IFNalpha, interleukin-2, interleukin-7, CTLA-4 (cytotoxic T-lympho

210 ependent type I interferon signaling and the interleukin-2/interleukin-2 receptor alpha pathway for t

211 ith Leishmania-specific interferon gamma and interleukin 2 levels, and negatively with Leishmania ski

212 Symptoms and plasma interleukin-2 levels increased significantly or near sig

213 Interleukin-2-mediated STAT5 phosphorylation in patients

214 explored 2 means to increase Tregs in cGVHD: interleukin-2/monoclonal antibody (IL-2/mAb) complexes a

215 h and without preactivation by interleukins (interleukin-2 or interleukin-6), was evaluated in the pr

216 lowing cGVHD therapies including prednisone, interleukin-2, or extracorporeal photophoresis.

217 m the fMLP signal, while only 15.2 or 22.2% (interleukin-2-or interleukin-6-activated) of preactivate

218 Inverse correlation with high-dose interleukin-2 outcomes was also observed for the CLEAR s

219 d NKp30/MAPK/IL-12 (interleukin-12) or IL-2 (interleukin-2) pathway was susceptible to NK lysis.

220 lonal antibodies (mAbs), phytohaemagglutinin/interleukin-2, phorbol 12-myristate 13-acetate/ionomycin

221 oly(I . C)LC induced potent multifunctional (interleukin 2-positive [IL-2(+)], tumor necrosis factor

222 (CD4+ interferon gamma-positive and/or CD4+ interleukin 2-positive responses in 45 of 111 [41%, 31.3

223 n levels of interferon gamma (IFN-gamma) and interleukin 2 produced by T-helper 1 cells when comparin

224 timulate P2X4 and P2X7 receptors that elicit interleukin 2 production and T cell proliferation.

225 ntagonistic feedback circuits that regulated interleukin 2 production in a manner dependent on T cell

226 interferon, tumor necrosis factor alpha, and interleukin-2 production and CD107(a/b) cytotoxic degran

227 activated T-cells (NFAT) transcription, and interleukin-2 production in Jurkat or primary T-cells.

228 Interleukin-2 production in mitogen-stimulated CD3(+) T

229 imilarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion

230 Old observations, such as the decreased interleukin-2 production, are better understood with our

231 k alleles, where ORMDL3 negatively regulated interleukin-2 production.

232 0, and mitogen-activated protein kinase, and interleukin-2 production.

233 , or a combination (29/37), elevated soluble interleukin 2 receptor (20/21), and elevated VEGF (16/20

234 genitors by augmenting responsiveness of the interleukin 2 receptor (IL-2R) and transcription factor

235 ells), which have abundant expression of the interleukin 2 receptor (IL-2R), are reliant on IL-2 prod

236 To compare the value of soluble interleukin 2 receptor (sIL-2R) with ACE as diagnostic b

237 that transmembrane secretory cargos, such as interleukin 2 receptor alpha subunit or Tac, transferrin

238 le tumor necrosis factor receptor 2, soluble interleukin 2 receptor alpha, soluble gp130, soluble CD2

239 ell depletion induction, 1635 (32%) received interleukin 2 receptor antagonist (IL2-RA), and 2596 (50

240 galovirus (CMV) infection compared with anti-interleukin 2 receptor antibody (anti-IL-2RA).

241 Additional knockout of interleukin 2 receptor common gamma chain (IL-2Rgammac)

242 odeficiency (SCID-X1) caused by mutations in interleukin 2 receptor gamma (IL2RG) gene threatens the

243 ransplantation into immunodeficient NOD/SCID/interleukin 2 receptor gamma chain null mice.

244 2Mit80, an interval that includes Il2ra (for interleukin 2 receptor, alpha chain), a gene that is kno

245 Here we identify human interleukin-2 receptor (IL-2R) beta chain (IL2RB) gene d

246 f a model PM protein, the alpha chain of the interleukin-2 receptor (Tac).

247 ecrosis factor receptor 2 (sTNF-R2), soluble interleukin-2 receptor alpha (sIL-2Ralpha), sCD27, B-cel

248 n, soluble interleukin-1 receptor I, soluble interleukin-2 receptor alpha, and tumor necrosis factor

249 recipients in 1999-2016 who received ATG or interleukin-2 receptor antagonist (IL2RA) for induction.

250 recipients in 1999-2016 who received ATG or interleukin-2 receptor antagonist (IL2RA) for induction.

251 e clearance was also similar between groups (interleukin-2 receptor antagonist group 56 +/- 20 mL/min

252 e low and similar between groups (10% in the interleukin-2 receptor antagonist group vs 6% in the RAT

253 antithymocyte globulin (RATG) compared with interleukin-2 receptor antagonists in a racially diverse

254 tandard induction immunosuppression was with interleukin-2 receptor antagonists, and antithymocyte gl

255 A total of 200 patients (n = 98 in the interleukin-2 receptor antagonists, and n = 102 in the R

256 lso distinguished patients who received anti-interleukin-2 receptor antibodies from those who receive

257 phenolate mofetil, corticosteroids, and anti-interleukin-2 receptor antibody induction, results in im

258 phenolate mofetil, corticosteroids, and anti-interleukin-2 receptor antibody induction, was associate

259 l as either rabbit antithymocyte globulin or interleukin-2 receptor antibody induction.

260 tely by increased immunosuppression and anti-interleukin-2 receptor antibody.

261 tion treatments (alemtuzumab, thymoglobulin, interleukin-2 receptor blockers, and no induction) given

262 is due to mutations in the gene encoding the Interleukin-2 receptor gamma chain (IL-2Rgamma), leading

263 of iCD8alpha cells depends on expression of interleukin-2 receptor gamma chain (IL-2Rgammac), IL-15,

264 rus-based gamma-retrovirus vector expressing interleukin-2 receptor gamma-chain (gammac) complementar

265 r-like effector nucleases (TALENs) to target interleukin-2 receptor subunit gamma (IL2RG) in pronucle

266 ody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 sign

267 rothrombin activity, urea, white blood cell, interleukin-2 receptor, indirect bilirubin, myoglobin, a

268 CD25, the alpha chain of the interleukin-2 receptor, is expressed in activated T cell

269 1beta, and interleukin-7) as well as soluble interleukin-2 receptor-alpha were significantly elevated

270 ry group, whereas interleukin-1beta, soluble interleukin-2 receptor-alpha, interleukin-4, interleukin

271 , rabbit antithymocyte globulin (r-ATG), and interleukin-2 receptor-antagonist.

272 IL-2 signals via interleukin-2 receptor-beta (IL-2Rbeta):IL-2Rgamma heter

273 FR, VEGFR, PDGFR, NGFR and IGF1R, as well as interleukin-2 receptor.

274 Although the clinical benefit of interleukin-2-receptor antibody (IL-2RAb) induction in r

275 eron gamma, tumor necrosis factor alpha, and interleukin 2) responses were discordant in frequency an

276 and CD8+ T cells and a higher proportion of interleukin 2-secreting cells (P = .01 and P = .002, res

277 and enhanced TCR-induced CD69 upregulation, interleukin-2 secretion, and proliferation to promote vi

278 Abnormalities in interleukin-2 signaling have been implicated in the path

279 Specifically, interleukin-2 signaling pathway mutations, including act

280 of the interleukin-2 receptor) and modulates interleukin-2 signaling.

281 alpha (tissue necrosis factor-alpha) and IL (interleukin)-2 soluble receptors and NT-proBNP (N-Termin

282 mune absorbent spot, gut-homing CD8 T cells, interleukin-2, symptoms, video capsule endoscopy, intrae

283 roducing HBsAg-specific interferon gamma and interleukin 2 (T-helper 1-type cytokine) and interleukin

284 ll differentiation by limiting the access of interleukin 2 to CD4(+) T cells, thereby enhancing Tfh c

285 co-operates with growth factor TGF-beta and interleukin-2 to activate Tet-mediated DNA demethylation

286 tumor necrosis factor alpha (TNF-alpha), and interleukin 2 together, compared with delayed vaccinatio

287 s with Childhood Acute Myeloid Leukemia with Interleukin-2 trials (age, 1-60 years).

288 4 cytokines evaluated (ie, interferon gamma, interleukin 2, tumor necrosis factor alpha, and granzyme

289 the functional diversity (ie, CD107, CD154, interleukin 2, tumor necrosis factor, and interferon gam

290 vely studying five effector functions (i.e., interleukin-2, tumor necrosis factor-alpha, interferon-g

291 g aspartate-directed protease 3 (caspase-3), interleukin-2, tumor necrosis factor-related apoptosis-i

292 rophage colony-stimulating factor) and IL-2 (interleukin-2), two pleiotropic cytokines of the mammali

293 ng on the well-characterized T-cell cytokine interleukin-2, we show how cytokine secretion and compet

294 eron gamma, tumor necrosis factor alpha, and interleukin 2 were quantified using intracellular cytoki

295 n gamma, tumor necrosis factor alpha, and/or interleukin 2, were present at the peak response.

296 lpha (TNF-alpha) but not interferon gamma or interleukin 2 which had a differentiated effector phenot

297 Interleukin-2, which conveys essential signals for immun

298 or-antigen-targeting antibody, a recombinant interleukin-2 with an extended half-life, anti-PD-1 and

299 oxin, two doses of an anti-CD25 immunotoxin (interleukin-2 with diphtheria toxin [IL-2-DT]), or two c

300 2 hours and then cultured in the presence of interleukin-2 with vehicle control or the SSRI (10(-6) m